BRCA2 and ovarian neoplasm: Recently, it was reported that a mutational “BRCAness” signature is a predictor for functional BRCA1/BRCA2 deficiency [36]; therefore, the 15 BRCA1/2 mutation-negative breast/ovarian tumors with a predominant COSMIC-signature 3 could be responsive to PARP inhibitors and platinum agents due to deficiency in DNA double strand break repair.